|
|
|

Tuesday, October 07, 2008
Latest
Anaphylactic Shock Medical and Health News Headlines
|
|
Anaphylactic Shock Medical and Health News Headlines
|
|
|
|
|
|
|
|
|
|
|
All Recent Anaphylactic Shock Medical Condition News Headlines |
|
|
|
|
|
|
Skin testing after anaphylaxis to a topical neosporin preparation
(Source: Annals of Allergy, Asthma and Immunology)...
POSTED 10/01/2008 at 06:01 AM --

|
Anaphylactic shock in a young woman with abnormal liver scans
(Source: Liver International)...
POSTED 09/30/2008 at 11:00 PM --

|
Skin testing performed in individuals cannot be compared with responses from anaphylactic patients.
Skin testing performed in individuals cannot be compared with responses from anaphylactic patients.
Anesth Analg. 2008 Oct;107(4):1441; author reply 1441
Authors: Dewachter P, Mouton-Faivre C
PMID: 18806067 [PubMed - in process] (Source: Anesthesia and Analgesia)...
POSTED 09/30/2008 at 11:00 PM --

|
Cefazolin: anaphylaxis: case report
(Source: Reactions)...
POSTED 09/30/2008 at 06:04 AM --

|
Emine saner on why hot chillis (probably) won't kill you
Emine Saner: 'It is possible to have an anaphylactic reaction but it is certainly not common,' says dietician Sue Baic (Source: Guardian Unlimited Science)...
POSTED 09/29/2008 at 06:11 PM --

|
Aprotinin in pediatric neuromuscular scoliosis surgery
Abstract Reduction of blood transfusions in patients with neuromuscular scoliosis can decrease potential complications such as immune
suppression, infection, hemolytic reaction and viral transmission. Aprotinin (Trasylol®, Bayer), an antifibrinolytic, has proven to be effective in reducing blood loss in cardiac and liver surgery, but little
data exists in patients undergoing spinal fusion for neuromuscular scoliosis. The purpose of this study was to evaluate the
safety and efficacy of aprotinin in pediatric neuromuscular scoliosis patients undergoing spinal fusion. The medical records
of all patients undergoing initial spinal fusions for neuromuscular scoliosis between January 1999 and March 2003 were reviewed
to determine demographic data, perioperative data, wound drainage and number of transfusion required. Cases were compared
to a matched group of historical controls. We had 14 patients in the aprotinin group and 17 in the control group. Total blood
loss in the aprotinin group was significantly lower compared to the control group (715 vs. 2,110 ml; P = 0.007). Significantly less blood loss occurred in the aprotinin group when blood loss per kilogram was evaluated as well
(23 vs. 60 ml/kg, respectively; P = 0.002). Intra-operative packed red blood cell (PRBC) transfusions were also significantly lower in the aprotinin group
(1.25 vs. 3.16 units; P = 0.001). No clinical evidence of anaphylaxis, deep vein thrombosis (DVT) or renal failure was observed in the aprotinin
group. After considering the price of drug therapy, operating room time, and the cost of blood products, the use of aprotinin
saved an average of $8,577 per patient. In our series, the use of aprotinin resulted in decreased blood loss and a decreased
rate of transfusions in children with neuromuscular scoliosis undergoing extensive spinal fusion. At out institution, the
use of aprotinin is safe and cost effective for patients with neuromuscular scoliosis.
Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00586-008-0790-yAuthors
Stepan Kasimian, Children’s Hospital Los Angeles 4650 Sunset Boulevard #69 Los Angeles CA 90027 USADavid L. Skaggs, Children’s Hospital Los Angeles 4650 Sunset Boulevard #69 Los Angeles CA 90027 USAWudbhav N. Sankar, Children’s Hospital Los Angeles 4650 Sunset Boulevard #69 Los Angeles CA 90027 USAJoseph Farlo, Children’s Hospital Los Angeles 4650 Sunset Boulevard #69 Los Angeles CA 90027 USAMashallah Goodarzi, Children’s Hospital Los Angeles 4650 Sunset Boulevard #69 Los Angeles CA 90027 USAVernon T. Tolo, Children’s Hospital Los Angeles 4650 Sunset Boulevard #69 Los Angeles CA 90027 USA
Journal European Spine JournalOnline ISSN 1432-0932Print ISSN 0940-6719 (Source: European Spine Journal)...
POSTED 09/29/2008 at 03:19 PM --

|
Mast cell-expressed orphan receptor ccrl2 binds chemerin and is required for optimal induction of ige-mediated passive cutaneous anaphylaxis
Mast cells contribute importantly to both protective and pathological IgE-dependent immune responses. We show that the mast cell–expressed orphan serpentine receptor mCCRL2 is not required for expression of IgE-mediated mast cell–dependent passive cutaneous anaphylaxis but can enhance the tissue swelling and leukocyte infiltrates associated with such reactions in mice. We further identify chemerin as a natural nonsignaling protein ligand for both human and mouse CCRL2. In contrast to other "silent" or professional chemokine interreceptors, chemerin binding does not trigger ligand internalization. Rather, CCRL2 is able to bind the chemoattractant and increase local concentrations of bioactive chemerin, thus providing a link between CCRL2 expression and inflammation via the cell-signaling chemerin receptor CMKLR1. (Source: The Journal of Experimental Medicine)...
POSTED 09/28/2008 at 11:00 PM --

|
[tako-tsubo syndrome after anaphylaxis caused by succinylcholine during general anaesthesia.]
[Tako-Tsubo syndrome after anaphylaxis caused by succinylcholine during general anaesthesia.]
Ann Fr Anesth Reanim. 2008 Sep 29;
Authors: Cabaton J, Rondelet B, Gergele L, Besnard C, Piriou V
The Tako-Tsubo syndrome (or transient left ventricular apical balloning) is a new clinical entity, very similar to acute myocardial infarction, but different by its excellent short-term prognosis. It has been reported after a physical or an emotional stress, and it is diagnosed by a coronary angiogram and a left ventriculography. We report here a case of Tako-Tsubo syndrome related to an anaphylactic shock caused by succinylcholine during general anaesthesia of a female patient, wearing an unadjustable gastric band.
PMID: 18829243 [PubMed - as supplied by publisher] (Source: Annales Francaises d'Anesthesie et de Reanimation)...
POSTED 09/28/2008 at 11:00 PM --

|
Herbal medicines: anaphylaxis: case report.
Page: 17 (Source: Reactions Weekly)...
POSTED 09/27/2008 at 06:13 AM --

|
Ige-mediated anaphylactic reactions to neuromuscular blocking agents: can they be prevented?
IgE-mediated anaphylactic reactions to neuromuscular blocking agents: Can they be prevented?
Content Type Journal ArticleCategory Invited CommentaryDOI 10.1007/s11882-008-0072-0Authors
E. FlorvaagS. G. O. Johansson, Karolinska University Hospital Department of Clinical Immunology Solna, L2:04 S-171 76 Stockholm Sweden
Journal Current Allergy and Asthma ReportsOnline ISSN 1534-6315Print ISSN 1529-7322
Journal Volume Volume 8
Journal Issue Volume 8, Number 5 / September, 2008 (Source: Current Allergy and Asthma Reports)...
POSTED 09/25/2008 at 02:33 AM --

|
Allergy to wheat and related cereals
Wheat is one of the major crops grown, processed and consumed by humankind and is associated with both intolerances (notably coeliac disease) and allergies. Two types of allergy are particularly well characterized. The first is bakers' asthma, which results from the inhalation of flour and dust during grain processing. Although a number of wheat proteins have been shown to bind IgE from patients with bakers' asthma, there is no doubt a well-characterized group of inhibitors of [alpha]-amylase (also called chloroform methanol soluble, or CM, proteins) are the major components responsible for this syndrome. The second well-characterized form of allergy to wheat proteins is wheat-dependent exercise-induced anaphylaxis (WDEIA), with the [omega]5-gliadins (part of the gluten protein fraction) being the major group of proteins which are responsible. Other forms of food allergy have also been reported, with the proteins responsible including gluten proteins, CM proteins and non-specific lipid transfer proteins. Processing of wheat and of related cereals (barley and rye, which may contain related allergens) may lead to decreased allergenicity while genetic engineering technology offers opportunities to eliminate allergens by suppressing gene expression. (Source: Clinical and Experimental Allergy)...
POSTED 09/23/2008 at 11:00 PM --

|
Dose-dependent food allergy induction against ovalbumin under acid-suppression: a murine food allergy model.
Dose-dependent food allergy induction against ovalbumin under acid-suppression: A murine food allergy model.
Immunol Lett. 2008 Sep 24;
Authors: Diesner SC, Knittelfelder R, Krishnamurthy D, Pali-Schöll I, Gajdzik L, Jensen-Jarolim E, Untersmayr E
BACKGROUND: Animal models are essential for analyzing the allergenic potential of food proteins and for investigating mechanisms underlying food allergy. Based on previous studies revealing acid-suppression medication as risk factor for food allergy induction, we aimed to establish a mouse model mimicking the natural route of sensitization in patients. METHODS: The effect of acid-suppressing medication on murine gastric pH was assessed by intragastric pH measurements after two injections of a proton pump inhibitor (PPI). To investigate dose-dependency, mice were fed different concentrations of ovalbumin (OVA; 0.2, 0.5, 1.0, 2.5 or 5.0mg) either with or without anti-ulcer medication. Additionally, different routes of exposure (i.p. vs. oral) were compared in a second immunization experiment. Sera were screened for OVA-specific antibody titers (IgG1, IgG2a and IgE) in ELISA and RBL assay. Clinical reactivity was evaluated by measuring rectal temperature after oral challenge and by type I skin tests. RESULTS: Two intravenous injections of PPI significantly elevated the gastric pH from 2.97 to 5.3. Only oral immunization with 0.2mg OVA under anti-acid medication rendered elevated IgG1, IgG2a and IgE titers compared to all other concentrations. Protein feeding alone altered antibody titers only marginally. Even though also i.p. immunizations induced high levels of specific IgE, only oral immunizations under anti-acids induced anaphylactic reactions evidenced by a significant decrease of body temperature. CONCLUSION: Only low-dosage ovalbumin feedings under anti-acid medication resulted in IgE mediated food allergy. Based on this knowledge we have established a suitable food allergy model for further investigations of food adverse reactions.
PMID: 18824031 [PubMed - as supplied by publisher] (Source: Immunology Letters)...
POSTED 09/23/2008 at 11:00 PM --

|
Understanding the mechanisms of anaphylaxis
The roles of key intermediate signaling components and mediators during and after mast cell activation and degranulation leading to anaphylaxis are identified.
Current Opinion in Allergy and Clinical Immunology (Source: Medscape Emergency Medicine Headlines)...
POSTED 09/22/2008 at 01:46 PM --

|
Human papillomavirus vaccine recombinant quadrivalent: first report of anaphylaxis: 10 case reports
(Source: Reactions)...
POSTED 09/22/2008 at 05:33 AM --

|
Mast cells and mast cell-derived factors in the regulation of allergic sensitization.
Mast cells and mast cell-derived factors in the regulation of allergic sensitization.
Chem Immunol Allergy. 2008;94:58-66
Authors: Taube C, Stassen M
Mast cells have been mainly regarded as effector cells in IgE-dependent mucosal immunity, including the host res - ponse to helminthic parasites but also the formidable and sometimes fatal anaphylactic reactions to inhaled or ingested allergens. Work performed mostly within the last decade revealed novel functions for mast cells as critical initi ators of fast inflammatory reactions upon IgE-independent activation. Thus, their role as a sentinel in innate immunity also suggests that mast cells are able to bridge innate and adaptive immunity. Herein, we will summarize the accumulating evidence that mast cells are also able to promote and to modu late the development of adaptive immune reactions with emphasis on their role in allergic sensitization in skin and lung. Based on murine data published so far, it is becoming apparent that mast cells and their mediators are of critical relevance for allergen sensitization under conditions which more closely resemble physiological contact with allergens. Yet, the function of mast cells can sometimes be bypassed using vigorous sensitization protocols, a finding which should be taken into account when animal models for complex human diseases are investigated.
PMID: 18802337 [PubMed - in process] (Source: Cell Research)...
POSTED 09/21/2008 at 03:57 AM --

|
Human papillomavirus vaccine recombinant quadrivalent: first report of anaphylaxis: 10 case reports.
Page: 14 (Source: Reactions Weekly)...
POSTED 09/20/2008 at 05:03 AM --

|
Adverse event reports following yellow fever vaccination.
Adverse event reports following yellow fever vaccination.
Vaccine. 2008 Sep 19;
Authors: Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, Marano N, Slade BA, Barnett ED, Brunette GW, Horan K, Staples JE, Kozarsky PE, Hayes EB
Yellow fever (YF) vaccine has been used for prevention of YF since 1937 with over 500 million doses administered. However, rare reports of severe adverse events following vaccination have raised concerns about the vaccine's safety. We reviewed reports of adverse events following YF vaccination reported to the U.S. Vaccine Adverse Event Reporting System (VAERS) from 2000 to 2006. We used estimates of age and sex distribution of administered doses obtained from a 2006 survey of authorized vaccine providers to calculate age- and sex-specific reporting rates of all serious adverse events (SAE), anaphylaxis, YF vaccine-associated neurotropic disease, and YF vaccine-associated viscerotropic disease. Reporting rates of SAEs were substantially higher in males and in persons aged >/=60 years. These findings reinforce the generally acceptable safety profile of YF vaccine, but highlight the importance of physician and traveler education regarding the risks and benefits of YF vaccination, particularly for travelers >/=60 years of age. Vaccination should be limited to persons traveling to areas where the risk of YF is expected to exceed the risk of serious adverse events after vaccination, or if not medically contraindicated, where national regulations require proof of vaccination to prevent introduction of YF.
PMID: 18809449 [PubMed - as supplied by publisher] (Source: Vaccine)...
POSTED 09/18/2008 at 11:00 PM --

|
Selective impairment of fc{varepsilon}ri-mediated allergic reaction in gads-deficient mice
Gads is a Grb2-like adaptor protein expressed in hematopoietic cells. We demonstrated that mast cells from Gads–/– mice have selective functional defects. Bone marrow-derived mast cells from Gads–/– mice failed to induce Ca2+ mobilization, degranulation and cytokine production upon cross-linking of FcRI. In vivo passive cutaneous anaphylaxis was also greatly impaired in Gads–/– mice. In contrast, Gads was dispensable for Toll-like receptor-mediated cytokine production in mast cells. Accordingly, mast cell-dependent resistance to acute peritoneal bacterial infection is not reduced in Gads–/– mice in vivo. Moreover, mature T and B cell responses and antibody production upon immunization were apparently normal in Gads–/– mice. Thus, inhibition of Gads in vivo would suppress the IgE-mediated allergic reaction with minimum adverse effects on both innate and acquired immune responses, and Gads could be an ideal target for the control of allergic responses. (Source: International Immunology)...
POSTED 09/17/2008 at 11:00 PM --

|
Highlights in nonhymenoptera anaphylaxis
New findings in both research and clinical practice of nonhymenoptera anaphylaxis with particular emphasis on food and drug allergy are reviewed.
Current Opinion in Allergy and Clinical Immunology (Source: Medscape Allergy Headlines)...
POSTED 09/17/2008 at 02:37 PM --

|
What do we know about the genetics of aspirin intolerance?
Although acetylsalicylic acid is prescribed for a broad range of diseases, it can induce a wide array of clinically recognized hypersensitivity reactions, including aspirin-intolerant asthma (AIA) with rhinitis and aspirin-intolerant urticaria (AIU) with anaphylaxis. Altered eicosanoid metabolism is the generally accepted mechanism of aspirin intolerance; the overproduction of cysteinyl leucotrienes has been suggested to play a causative role in both AIA and AIU. Genetic markers suggested for AIA include HLA-DPBI*0301, leucotriene C4 synthase (LTC4S), ALOX5, CYSLT, PGE2, TBXA2R and TBX21. Similarly, HLA-DB1*0609, ALOX5, FCER1A and HNMT have been identified as possible genetic markers for AIU. An additional low-risk genetic marker for AIA is MS4A2, which encodes the beta-chain of FCER1. Other single and sets of two or more interacting genetic markers are currently being investigated. Analyses of the genetic backgrounds of patients with AIA and AIU will promote the development of early diagnostic and therapeutic interventions, which may reduce the incidence of AIA and AIU. (Source: Journal of Clinical Pharmacy and Therapeutics)...
POSTED 09/15/2008 at 11:00 PM --

|
|
|
|
|
|
|
|
 |
|
|
|
|
|
IMPORTANT NOTICE: The information provided on this site is intended for your general knowledge only and is not a substitute for professional
medical advice or treatment for specific medical conditions. You should not use this information to diagnose or treat a health problem or disease without consulting with a
qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition.
|
|
|
|
|
|
|
|
Featured Product! |
 |
|
Total Balance
Men's Plus |
|
"The restoration and maintenance of normal organ and brain function, a strong immune system, and the balancing of hormones is the key to vibrant health and in avoiding premature-aging!" |
|
CLICK HERE for more info... |
|
|